InvestorsHub Logo
Followers 45
Posts 1517
Boards Moderated 0
Alias Born 11/25/2013

Re: None

Sunday, 05/23/2021 6:11:01 PM

Sunday, May 23, 2021 6:11:01 PM

Post# of 428989
Both interim analysis of R-IT were statistically solid showing benefits but DMC continued so that the data would be “uncontestable”. I guess nobody told Steve.
“Allowing the REDUCE-IT data set to mature fully provided physicians and patients with uncontestable, robust, consistent, and reliable efficacy and safety data upon which to base clinical decisions for use of icosapent ethyl in cardiovascular risk reduction.”



https://academic.oup.com/ehjcvp/article/7/3/e61/5917630
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News